Bendesky A, Menéndez D

Language: Spanish
References: 70
Page: 255-259
PDF size: 50.39 Kb.

Text Extraction

No abstract

REFERENCES

1. Dobiás L, Cerná M, Rössner P et al. Genotoxicity and carcinogenicity of metronidazole. Mutat Res 1994; 317: 177-194.

2. Cosar C, Julou L. Activitiè de1’(hydroxy-2-ethyl)-1-methyl-2-nitro-5-imidazole (8.823R.P.) vis-a-vis des infections expérimentales à Trichomonas vaginalis. Ann Inst Pasteur (Paris) 1959; 96: 238-241.

3. Ralph ED, Darwish R, Austin TW et al. Susceptibility of Trichomonas vaginalis strains to metronidazole: response to treatment. Sex Transm Dis 1983; 10: 119-122.

4. Sears SD, O’Hare J. In vitro susceptibility of Trichomonas vaginalis to 50 antimicrobial agents. Antimicrob Agents Chemother 1988; 32: 144-146.

5. Khambatta RB. Metronidazole in giardiasis. Ann Trop Med Parasitol 1971; 65: 487-489.

6. Jikipii L, Jokipii AM. In vitro susceptibility of Giardia lamblia trophozoites to metronidazole and tinidazole. J Infec Dis 1980; 141: 317-325.

7. Powell SJ, McLeod I, Wilmontt AJ, Elsdon-Drew R. Metronidazole in amoebic dysentery and hepatic liver abscess. Lancet 1966; 2: 1329-1331.

8. Mahajan RC, Chitkara NL, Vinayak VK. In vitro comparative evaluation of tinidazole and metronidazole strains of Entamoeba histolytica. Indian J Pathol Bacteriol 1974; 17: 226-228.

9. Aldrige KE, Gelfand M, Reller LB et al. A five year multicenter study of the susceptibility of the Bacteroides fragilis group isolates to cephalosporins, cephamycins, penicillins, clindamycin and metronidazole in the United States. Diagn Microbiol Infect Dis 1994; 18: 235-241.

10. Appelbaum PC, Spangler SK, Jacobs MR. b-lactamase production and susceptibilities to amoxicillin, amoxicillin-clavulanate, ticarcillin, ticarcillin-clavulanate, cefoxitin, imipenem and metronidazole of 320 non-Bacteroides fragilis Bacteroides isolates and 129 fusobacteria from 28 U.S. centers. Antimicrob Agents Chemother 1990; 34: 1546-1550.

11. Pavicic MJ, van Winkelhoff AJ, de Graaff J. In vitro susceptibilities of Actinobacillus actinomycetem comitans to a number of antimicrobial combinations. Antimicrob Agents Chemother 1992; 36: 2634-2638.

12. Freydiere AM, Gillie Y, Tigaud S et al. In vitro susceptibilities of 40 Campylobacter fetus subs. Jejuni strains to niridazole and metronidazole. Antimicrob Agents Chemother 1984; 25: 145-146.

13. Lopez-Brea M, Martin E, Lopez-Lavid C et al. Susceptibility of Helicobacter pylori to metronidazole. Eur J Clin Microbiol Infec Dis 1991; 10:1082-1083.

14. Moore RA, Beckthold B, Bryan LE. Metronidazole uptake in Helicobacter pylori. Can J Microbiol 1995; 41: 746-749.

15. Frasser AG, Sim R, Sankey EA, Dhillon AP, Pounder RE. Effect of eradication on Helicobacter pylori on gastric epithelial cell proliferation. Aliment Pharmacol Ther 1994; 8: 167-173.

16. Jones BM, Geary I, Alawattegama AB et al. In vitro and in vivo activity of metronidazole against Gardnerella vaginalis, Bacteroides ssp and Mobiluncus ssp. in bacterial vaginosis. J Antimicrob Chemother 1985; 16: 189-97.

17. Wexler HM, Finegold SM. In vitro activity of cefotetan compared with that of other antimicrobial agents against anaerobic bacteria. Antimicrob Agents Chemother 1988; 32: 601-604.

18. Pankuch GA, Jacobs MR, Appelbaum PC. Susceptibilities of 428 gram-positive and gram-negative anaerobic bacteria to Bay y3118 compared with their susceptibilities to ciprofloxacin, clindamycin, metronidazole, piperacillin, piperacillin-tazobactam and cefoxitin. Antimicrob Agents Chemother 1993; 37: 1649-1654.

19. Prantera C, Berto E, Scribano ML, Falasco G. Use of antibiotics in the treatment of active Crohn’s disease: experience with metronidazole and ciprofloxacin. Ital J Gastroenterol Hepatol 1998; 30: 602-606.

20. Bleicher PA, Charles JH, Sober AJ. Topical metronidazole for rosacea. Arch Dermatol 1987; 123: 609-14.

21. Nielsen PG. Topical metronidazole gel: use in acne vulgaris. Int J Dermatol 1994; 30: 662-6.

22. Veien NK, Munkvad JM, Nielsen AO et al. Topical metronidazole in the treatment of perioral dermatitis. J Am Aca Dermatol 1991; 24: 258-60.

23. Wilson RL, Cramp WA, Ings RM. Metronidazole (“Flagyl”): mechanisms of radiosensitization. Int J Raidat Biol 1974; 26: 557-69.

24. Teicher BA, Herman TS, Shulman L, Bubley G, Coleman CN, Frei E. Combination of metronidazole with cyclophosphamide and platinum complexes. Cancer Chemother Pharmacol 1991; 28: 153-58.

25. Müller M. Mode of action of metronidazole on aerobic bacteria and protozoa. Surgery 1983; 93: 165-71.

26. Samuelson J. Why metronidazole is active against both bacteria and parasites. Antimicrob Agents Chemother 1999; 43: 1533-41.

27. Bergan T, Arnold E. Pharmacokinetics of metronidazole in healthy volunteers after tablets and suppositories. Chemotherapy 1980; 26: 231-41.

28. Houghton GW, Smith J, Thorne PS et al. The pharmacokinetics of oral and intravenous metronidazole in man. J Antimicrob Chemother 1979; 5: 621-3.

29. Houghton GW, Thorne PS, Smith J et al. Plasma metronidazole concentrations after suppository administration. In: Philips Y, Collier J, editores. Metronidazole: proceedings of the Second International Symposium on Anaerobic Infections. Academic Press, Mew York. Royal Society of Medicine 1979: 41-44.

30. Ti TY, Lee HS, Khoo YM. Disposition of intravenous metronidazole in Asian surgical patients. Antimicrob Agents Chemother 1996; 40: 2248-51.

31. Cunnigham FE, Kraus DM, Brubaker L et al. Pharmacokinetics of intravaginal metronidazole gel. J Clin Pharmacol 1994; 34: 1060-5.

32. Mattila J, Männistö PT, Mäntylä R et al. Comparative pharmacokinetics of metronidazole and tinidazole as influenced by administration route. Antimicrob Agents Chemotherapy 1983; 23: 721-5.

33. Schmadel K, McEvoy GK. Topical metronidazole: a new therapy for rosacea. Clin Pharm 1990; 9: 94-101.

34. Schwartz DE, Jeunet F. Comparative pharmacokinetics studies of ornidazol and metronidazole in man. Chemotherapy 1976; 22: 19-29.

35. Lau AH, Lam NP, Piscitelli SC. Clinical pharmakokinetics of metronidazole and other nitroimidazole anti-infectives. Clin Pharmacokinet 1992; 23: 328-64.

36. Loft S, Dossing M, Poulsen H et al. Influence of dose and route of administration on disposition of metronidazole and its metabolites. Eur J Clin Pharmacol 1986; 30: 467-73.

37. Kokipii AM, Myllyla VV, Hokkanen E et al. Penetration of the blood barrier by metronidazole and tinidazole. J Antimicrob Chemother 1977; 3: 239-45.

38. Heisterberg L, Branebjerg PE. Blood and milk concentrations of metronidazole in mothers and infants. J Perinat Med 1983; 11: 114-20.

39. Stambaugh JE, Feo LG, Manthei RW. The isolation and identification of the urinary oxidative of metronidazole in man. J Pharmacol Exp Ther 1968; 161: 373-6.

40. Loft S. Metronidazole and antipyrine as probes for the study of foreign compound metabolism. Pharmacol Toxicol 1990; 66: 3-31.

41. Andersen M, Binderup M, Kiel P, Larsen H. Mutagenicity of metronidazole. Arch Pharm Chem Sci Ed 1982; 10: 25-44.

42. Rosenblatt JE, Edson RS. Metronidazole, Mayo Clin Proc 1983; 58:154-157.

43. Rowland IR. Factors affecting metabolic activity of the intestinal microflora. Drug Metab Rev 1988; 19: 243-61.

44. Bergan T, Throsteinsson SB. The pharmacokinetics of metronidazole and its metabolites in reduced renal function. Chemotherapy 1986; 32: 305-18.

45. Tu YH, Wang Y, Allen Jr LV, Albers DD, Gorgin MK. Pharmacokinetics of metronidazole administered intravenously to male rats. Int J Pharmaceut 1990; 61: 119-125.

46. Lykkegaard-Nielsen N, Jutesen T. Excretion of metronidazole in human bile. Investigation of hepatic bile, common duct bile and gallbladder bile. Scand J Gastroenterol 1977; 12: 1002-8.

47. Knov V, Nord CE. Concentrations of tinidazole and metronidazole in serum saliva and alveolar bone. J Antimicrob Chemother 1982 10: suppl. A, 165-72.

48. Freeman CD, Klutman NE, Lamp KC. Metronidazole: a therapeutic review and uptake. Drugs 1997; 54: 679-708.

49. Goldstein JA, de Morais SMF. Biochemistry and molecular biology of the human CYP 2C subfamily, Pharmacogenetics 1994; 4: 285-99.

50. Williams CS, Woodcock KR. Do ethanol and metronidazole interact to produce a disulfiram-like reaction? Ann Pharmacother 2000; 34: 255-7.

51. Eland IA, van Puijenbroek EP, Sturkenboom MJ, Wilson JH, Stricker BH. Drug-associated acute pancreatitis: twenty-one years of spontaneous reporting in The Netherlands. Am J Gastroenterol 1999; 94: 2417-22.

52. Bost RG. Metronidazole: toxicology and teratology. In: SM Finegold, editor. metronidazole Proceedings of the International metronidazole Conference, Montreal. 1977: 126-31.

53. Mudry MD, Martinez-Flores I, Palermo AM et al. Embryolethality induced by metronidazole (MTZ) in Rattus norvegicus. Teratog Carcinog Mutagen 2001; 21: 197-205.

54. Diav-Citrin O, Shechtman S, Gotteiner T, et al. Pregnancy outcome after gestational exposure to metrondiazole: A prospective controlled cohort study. Teratology 2001; 63: 186-92.

55. Caro-Paton T, Carvajal A, Martin de Diego I et al. Is metronidazole teratogenic? A meta-analysis. Br J Clin Pharmacol 1997; 44: 179-82.

56. Goodman & Gilman’s. The pharmacological basis of therapeutics. Eight ed. 1992: 1004.

57. De Meo M, Vanelle P, Bernardini E, Laget M, Maldonado J, Jentzer O, Crozet MP, Dumenil G. Evaluation on mutagenic and genotoxic activities of 48 nitroimidazoles and related imidazole derivates by the Ames test and the SOS chromotest. Envir Mol Mut 1992; 19: 167-70.

58. Fahring R, Engelke M. Reinvestigation of in vivo genotoxicity studies in man. I. No induction of DNA strand breaks in peripheral lymphocytes after metronidazole therapy. Mutat Res 1997; 395: 219-21.

59. Ostrosky-Wegman P, Lares I, Santiago P. Metronidazole hprt mutation induction in sheep and the relationship with its elimination rate. Mut Res 1994; 307: 253-9.

60. Elizondo G, Gonsebatt ME, Salzar AM, Lares I, Santiago P, Herrera J, Hong E, Ostrosky-Wegman P. Genotoxic effects of metronidazole. Mutat Res 1996; 370: 75-80.

61. Ré JL, De Méo MP, Laget M et al. Evaluation of the genotoxic activity of metronidazole and dimetridazole in human lymphocytes by the comet assay. Mutat Res 1997; 375: 147-55.

62. Reitz M, Rumpf M, Knitza R. Metronidazole induces DNA strandbreaks in cultures of human lymphocytes and phytohemagglutininstimulated human lymphocytes. Drug Res 1991b; 41: 65-9.

63. Menéndez D, Rojas E, Herrera LA et al. DNA breakage due metronidazole treatment. Mutat Res 2001; 478:153-8.

64. IARC. Evaluation of carcinogenic risk to human. International Agency for Research on Cancer. Lyon, France. 1987: Supp. 7.

65. Rustia M y Shubik P. Experimental Induction of hepatomas, mammary tumors, and other tumors with metronidazole in noninbred Sas:MRC(WI)BR rats. J Natl Can Inst 1979; 63: 863-867.

66. WHO Pharmaceuticals Newsletters 3&4, World Health Organization 1998.

67. Beard CM, Noller KL, o’Fallon WM, Kurland L, Dockerty MB. Lack of evidence for cancer due to use of metronidazole. N Engl J Med 1979; 301: 519-22.

68. Danielson DA, Hannan MT, Jick H. Metronidazole and cancer. J Am Med Assoc 1982; 247: 2498-9.

69. Thapa PB, Whitlock JA, Brockman KG et al. Prenatal exposure to metronidazole and risk of childhood cancer. Cancer 1998; 83: 1461-8.

70. Beard CM, Noller KL, O’Fallon WM et al. Cancer after exposure to metronidazole. Mayo Clin Proc 1988; 63: 147-153.